Onyx Biotec Limited IPO Allotment Status
The allotment date for the Onyx Biotec Limited IPO is set for November 19, 2024, with shares priced at a range from ₹58 to ₹61 per share and a face value of ₹10. The offering consists of lots of 2000 shares, with bids accepted for these lots or their multiples.
Onyx Biotec Limited IPO Allotment Status Check
To ascertain their allocation status for the Onyx Biotec Limited IPO, investors can easily navigate through steps provided on either the BSE platform or the IPO registrar Mas Services Limited Link.
IPO Allotment Status BSE
Here are steps to check Onyx Biotec Limited IPO allotment status on BSE website
Step 1: Visit BSE website
Step 2: Select ‘Equity’ under the Issue Type
Step 3: Choose Onyx Biotec Limited from the drop-down menu
Step 4: Enter Application No or PAN
Step 5: Click on ‘I am not a Robot’ and then hit on ‘Submit”
Steps to check Onyx Biotec Limited allotment status on Mas Services Limited
Step 1: Visit IPO registrar website – Mas Services Limited
Step 2: Select ‘Onyx Biotec Limited’ from the Select Company dropdown menu
Step 3: Choose from PAN, Application No, DP/Client ID, or Account No/IFSC
Step 4: Enter the details as per the option selected
Step 5: Hit the Submit button
Your Onyx Biotec Limited IPO allotment status will be reflected on the screen.
Onyx Biotec Limited IPO GMP Today
Onyx Biotec Limited IPO GMP (Grey Market Premium) is ₹10 as of November 19, 2024.
Onyx Biotec Limited IPO Subscription Status
Onyx Biotec Ltd IPO Day 3 subscription status revealed 184.60 times overall subscription. This early interest reflects investor confidence in the company’s market prospects and growth potential.
Onyx Biotec Limited IPO Details
Onyx Biotec IPO is a book-built issue of Rs 29.34 crores with a fresh issue of 48.1 lakh shares. Bidding ran from November 13-18, 2024, with a price band of ₹58 – ₹61 per share. Horizon Management Private Limited leads the Onyx Biotec IPO, with Mas Services Limited as registrar and Giriraj Stock Broking as market maker.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.